Developing a better vaccine for influenza using advanced particles
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
This study is working on a new flu vaccine that uses tiny particles to help your body respond better to the vaccine, making it more effective against different strains of the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10762420 on NIH RePORTER |
What this research studies
This research focuses on creating an improved influenza vaccine by optimizing the immune response through the use of nano/microparticles made from a special polymer called acetalated dextran. The researchers aim to enhance how the vaccine components are released in the body, which is crucial for generating a strong immune response. By fine-tuning the degradation rates of both the vaccine's antigen and its adjuvant, they hope to significantly improve the effectiveness of the vaccine against various strains of influenza. This approach is designed to address the limitations of current seasonal vaccines that often fail due to changes in the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at high risk for influenza, such as the elderly, young children, and those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already received a seasonal flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and long-lasting influenza vaccine, potentially reducing the number of infections and deaths caused by the virus.
How similar studies have performed: Other research has shown promise in using similar nanoparticle approaches for vaccine development, indicating potential for success in this area.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Ainslie, Kristy M — Univ of North Carolina Chapel Hill
- Study coordinator: Ainslie, Kristy M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.